FORMELA JEAN FRANCOIS — SEC insider filings
SEC reporting owner CIK 1030575. 33 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2020-08-27 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 125,000 shares, $2,000,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 74 legs across 18 filings — 4,345,172 shares, $240,648,015 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
- Largest priced transaction: sale of 2,055,063 shares @ $38.00 ($78,092,394) in Translate Bio, Inc., filed 2021-09-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | Director | 8 | — | 34 legs · 1,605,321 sh · $151,206,237 | 4 |
| Translate Bio, Inc. (TBIO) | Director | 4 | — | 7 legs · 2,283,052 sh · $82,922,315 | 5 |
| Korro Bio, Inc. (KRRO) | Director | 13 | — | 30 legs · 430,521 sh · $6,133,892 | 7 |
| Ikena Oncology, Inc. (IKNA) | Director | 6 | 1 leg · 125,000 sh · $2,000,000 | 3 legs · 26,278 sh · $385,572 | 12 |
| Spero Therapeutics, Inc. (SPRO) | Director | 2 | — | — | 2 |
Insider filings — FORMELA JEAN FRANCOIS
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 19,042 @ $15 · Sale (S): 2,984 @ $15.60 · Sale (S): 3,944 @ $15 · Sale (S): 617 @ $15.60 · Sale (S): 33,175 @ $14.30 · Sale (S): 6,870 @ $14.30 | EDGAR |
| 2026-09-15 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 8,450 @ $13.99 · Sale (S): 1,750 @ $13.99 · Sale (S): 31,888 @ $14.12 · Sale (S): 6,602 @ $14.12 | EDGAR |
| 2026-08-28 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 249 @ $13.96 · Sale (S): 51 @ $13.96 | EDGAR |
| 2026-08-21 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 23,584 @ $14 · Sale (S): 4,884 @ $14 | EDGAR |
| 2026-08-13 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 1,775 @ $13.96 · Sale (S): 368 @ $13.96 | EDGAR |
| 2026-07-07 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 85,955 @ $14.03 · Sale (S): 14,745 @ $14.03 · Sale (S): 817 @ $13.96 · Sale (S): 8,506 @ $13.96 | EDGAR |
| 2026-06-24 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 3,382 @ $13.95 · Sale (S): 580 @ $13.95 · Sale (S): 101,579 @ $14.25 · Sale (S): 17,426 @ $14.25 · Sale (S): 40,679 @ $14.60 · Sale (S): 666 @ $14.98 · +2 more | EDGAR |
| 2026-06-11 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 14,677 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Korro Bio, Inc. (KRRO) | Sale (S): 2,441 @ $13.95 · Sale (S): 419 @ $13.95 | EDGAR |
| 2025-06-12 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 6,010 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 5,190 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Ikena Oncology, Inc. (IKNA) | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 17,857 @ $56 | EDGAR |
| 2023-11-07 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 942,075 · Grant/award (A): 177,217 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Ikena Oncology, Inc. (IKNA) | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 5,197 @ $0 · Grant/award (A): 7,688 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Ikena Oncology, Inc. (IKNA) | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | Ikena Oncology, Inc. (IKNA) | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2021-12-14 | 4 | Ikena Oncology, Inc. (IKNA) | Purchase (P): 125,000 @ $16 · Sale (S): 11,989 @ $15.03 · Sale (S): 8,330 @ $14.64 · Sale (S): 5,959 @ $14 | EDGAR |
| 2021-09-14 | 4 | Translate Bio, Inc. (TBIO) | Sale (S): 2,055,063 @ $38 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 · Sale (S): 37,800 (derivative) @ $0 | EDGAR |
| 2021-08-18 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 26,019 @ $127.02 · Sale (S): 55,525 @ $127.79 · Sale (S): 56,280 @ $128.77 · Sale (S): 48,724 @ $129.88 · Sale (S): 66,468 @ $130.79 · Sale (S): 53,823 @ $131.82 · +12 more | EDGAR |
| 2021-06-25 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 2,094 @ $0 · Grant/award (A): 3,382 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Translate Bio, Inc. (TBIO) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-15 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 29,071 @ $85.18 · Sale (S): 1,875 @ $85.98 · Sale (S): 16,293 @ $85.92 · Sale (S): 47,422 @ $86.73 · Sale (S): 93,102 @ $87.75 · Sale (S): 13,309 @ $88.70 · +1 more | EDGAR |
| 2021-04-30 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 4,513 @ $85.43 | EDGAR |
| 2021-04-28 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 806 @ $84.93 · Sale (S): 79,714 @ $85.39 · Sale (S): 68,836 @ $86.41 · Sale (S): 61,680 @ $87.08 · Sale (S): 102,186 @ $85.40 · Sale (S): 29,740 @ $86.12 | EDGAR |
| 2021-04-07 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 800 @ $84.98 | EDGAR |
| 2021-04-01 | 4 | Ikena Oncology, Inc. (IKNA) | Conversion (C): 2,901,609 · Conversion (C): 1,099,118 · Conversion (C): 749,634 · Grant/award (A): 5,362,888 (derivative) @ $1.40 · Conversion (C): 9,499,999 (derivative) · Conversion (C): 11,258,117 (derivative) · +2 more | EDGAR |
| 2021-03-01 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 501,945 @ $60.29 | EDGAR |
| 2020-12-23 | 4 | Translate Bio, Inc. (TBIO) | Sale (S): 56,536 @ $25.50 · Sale (S): 79,865 @ $25.04 · Sale (S): 2,700 @ $25.88 | EDGAR |
| 2020-10-27 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2020-08-27 | 4 | Translate Bio, Inc. (TBIO) | Sale (S): 34,410 @ $15.00 · Sale (S): 44,381 @ $14.80 · Sale (S): 10,097 @ $14.38 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1030575 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs